• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头孢唑肟在持续非卧床腹膜透析中的消除动力学

Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis.

作者信息

Gross M L, Somani P, Ribner B S, Raeader R, Freimer E H, Higgins J T

出版信息

Clin Pharmacol Ther. 1983 Nov;34(5):673-80. doi: 10.1038/clpt.1983.231.

DOI:10.1038/clpt.1983.231
PMID:6313276
Abstract

We investigated the kinetics of ceftizoxime, a beta-lactamase stable cephalosporin, in eight subjects undergoing continuous ambulatory peritoneal dialysis (CAPD). A single 500-mg or 1-gm dose was injected IV, or a 500-mg dose was given intraperitoneally in the CAPD fluid during a 6-hr dwell time. The ceftizoxime (500 mg) serum kinetic parameters were as follows: peak concentrations, 21 to 46 mg/l; volume of distribution, 0.27 l/kg; elimination rate constant, 0.0784 hr-1; plasma clearance, 1.66 l/kg hr-1; and t1/2, 10.2 hr. The t1/2 after 1 gm was 12 hr. Dialysate ceftizoxime concentrations rose rapidly between 0.25 and 2 hr and slowly over the next 4 hr, but only 4.04 +/- 1.8 and 7.4 +/- 2.9 mg ceftizoxime/hr was eliminated by the peritoneal route over a 6-hr dwell time after 500 mg or 1 gm IV. This represents only 4% to 5% of the dose. After intraperitoneal instillation, the antibiotic appeared in the serum within 15 min in all four subjects, and the peak serum concentrations ranged from 12 to 19.8 mg/l (mean +/- SD = 16.4 +/- 3.3) between 5 and 6 hr. Approximately 78% of ceftizoxime was absorbed from the peritoneal dialysis fluid during a single 6-hr dwell time. Rate constant for absorption, ka, was 0.3959 hr-1 and absorption t1/2 was 1.75 hr (as calculated by the residual equation). These data suggest that ceftizoxime has bidirectional exchange characteristics through the peritoneal membrane. Instillation of ceftizoxime in CAPD fluid alone may permit rapid absorption to reach therapeutic serum concentrations.

摘要

我们研究了头孢唑肟(一种对β-内酰胺酶稳定的头孢菌素)在8名持续非卧床腹膜透析(CAPD)患者体内的动力学。静脉注射单次剂量500毫克或1克,或在CAPD液中于6小时留腹期间给予500毫克腹腔内注射。头孢唑肟(500毫克)的血清动力学参数如下:峰值浓度为21至46毫克/升;分布容积为0.27升/千克;消除速率常数为0.0784小时-1;血浆清除率为1.66升/千克·小时-1;半衰期为10.2小时。1克剂量后的半衰期为12小时。透析液中头孢唑肟浓度在0.25至2小时迅速上升,随后4小时缓慢上升,但静脉注射500毫克或1克后,在6小时留腹期间经腹膜途径仅消除4.04±1.8和7.4±2.9毫克头孢唑肟/小时。这仅占剂量的4%至5%。腹腔内滴注后,所有4名受试者在15分钟内血清中出现抗生素,5至6小时之间血清峰值浓度范围为12至19.8毫克/升(均值±标准差=16.4±3.3)。在单次6小时留腹期间,约78%的头孢唑肟从腹膜透析液中吸收。吸收速率常数ka为0.3959小时-1,吸收半衰期为1.75小时(由残差方程计算)。这些数据表明头孢唑肟通过腹膜具有双向交换特性。仅在CAPD液中滴注头孢唑肟可能允许快速吸收以达到治疗性血清浓度。

相似文献

1
Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis.头孢唑肟在持续非卧床腹膜透析中的消除动力学
Clin Pharmacol Ther. 1983 Nov;34(5):673-80. doi: 10.1038/clpt.1983.231.
2
Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1985 Sep;38(3):285-9. doi: 10.1038/clpt.1985.172.
3
Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析期间庆大霉素从腹膜的单向吸收
Clin Pharmacol Ther. 1982 Jul;32(1):113-21. doi: 10.1038/clpt.1982.134.
4
Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.慢性非卧床腹膜透析患者静脉及腹腔注射莫拉司亭的药代动力学
Eur J Clin Pharmacol. 1986;30(3):299-302. doi: 10.1007/BF00541532.
5
Pharmacokinetics of intravenous ceftizoxime in patients on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患者静脉注射头孢唑肟的药代动力学
Clin Nephrol. 1985 Mar;23(3):120-4.
6
Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.头孢唑肟在持续非卧床腹膜透析患者中的药代动力学
Antimicrob Agents Chemother. 1983 Aug;24(2):237-9. doi: 10.1128/AAC.24.2.237.
7
Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析期间腹腔内和静脉注射头孢哌酮的药代动力学
Clin Pharmacol Ther. 1984 Feb;35(2):208-13. doi: 10.1038/clpt.1984.28.
8
Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis.头孢噻肟在血液透析和持续性非卧床腹膜透析患者中的药代动力学
J Antimicrob Chemother. 1984 Sep;14 Suppl B:135-42. doi: 10.1093/jac/14.suppl_b.135.
9
Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析的慢性肾衰竭患者腹腔注射替考拉宁的药代动力学
Br J Clin Pharmacol. 1988 Jun;25(6):761-5. doi: 10.1111/j.1365-2125.1988.tb05265.x.
10
Moxalactam kinetics during chronic ambulatory peritoneal dialysis.慢性非卧床腹膜透析期间的头孢氧哌唑动力学
Clin Pharmacol Ther. 1983 Sep;34(3):403-7. doi: 10.1038/clpt.1983.187.

引用本文的文献

1
Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?腹腔内给药途径:在实验动物研究中是否应该使用?
Pharm Res. 2019 Dec 23;37(1):12. doi: 10.1007/s11095-019-2745-x.
2
Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth.经过基因工程改造以表达Tum-5的Nissle 1917能够抑制小鼠黑色素瘤的生长。
Oncotarget. 2017 Aug 24;8(49):85772-85782. doi: 10.18632/oncotarget.20486. eCollection 2017 Oct 17.
3
Cefepime clinical pharmacokinetics.头孢吡肟的临床药代动力学。
Clin Pharmacokinet. 1993 Aug;25(2):88-102. doi: 10.2165/00003088-199325020-00002.
4
Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review.持续非卧床腹膜透析的药代动力学研究进展:文献综述
Pharm Weekbl Sci. 1984 Dec 14;6(6):229-36. doi: 10.1007/BF01954550.
5
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.接受腹膜透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
6
Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢唑肟:抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1985 Apr;29(4):281-329. doi: 10.2165/00003495-198529040-00001.
7
Clinical pharmacokinetics of the third generation cephalosporins.第三代头孢菌素的临床药代动力学
Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001.
8
Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):479-83. doi: 10.1007/BF00613528.
9
Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.慢性非卧床腹膜透析患者静脉及腹腔注射莫拉司亭的药代动力学
Eur J Clin Pharmacol. 1986;30(3):299-302. doi: 10.1007/BF00541532.
10
Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis.亚胺培南-西司他丁在持续性非卧床腹膜透析的肾功能不全患者中的药代动力学。
Antimicrob Agents Chemother. 1988 Apr;32(4):530-4. doi: 10.1128/AAC.32.4.530.